Page 113 - Read Online

Oboma et al. J Transl Genet Genom. 2025;9:62-75 https://dx.doi.org/10.20517/jtgg.2024.74 Page 74

18. Runcie KD, Dallos MC. Prostate Cancer immunotherapy-finally in from the cold? Curr Oncol Rep. 2021;23:88. DOI PubMed
19. Kanu GA, Parambath JBM, Abu Odeh RO, Mohamed AA. Gold nanoparticle-mediated gene therapy. Cancers. 2022;14:5366. DOI
PubMed PMC
20. Allami P, Heidari A, Rezaei N. The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma. Front
Mol Biosci. 2022;9:1083645. DOI PubMed PMC
21. Beach MA, Nayanathara U, Gao Y, et al. Polymeric nanoparticles for drug delivery. Chem Rev. 2024;124:5505-616. DOI PubMed
PMC
22. Bajpai S, Tiwary SK, Sonker M, et al. Recent advances in nanoparticle-based cancer treatment: a review. ACS Appl Nano Mater.
2021;4:6441-70. DOI
23. Lee NH, You S, Taghizadeh A, Taghizadeh M, Kim HS. Cell membrane-cloaked nanotherapeutics for targeted drug delivery. Int J
Mol Sci. 2022;23:2223. DOI PubMed PMC
24. Kadry MO, Abdel-Megeed RM. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer
therapy via liposomal-coated compounds. Plos One. 2024;19:e0302264. DOI PubMed PMC
25. Zhang H, Qin C, An C, et al. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy
of cancer. Mol Cancer. 2021;20:126. DOI PubMed PMC
26. Tabibian M, Moghaddam FS, Motevaseli E, et al. Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology
with a special focus on androgen receptor signaling. Cell Commun Signal. 2024;22:504. DOI PubMed PMC
27. Kumari S, Sharma V, Tiwari R, Maurya JP, Subudhi BB, Senapati D. Therapeutic potential of p53 reactivation in prostate cancer:
strategies and opportunities. Eur J Pharmacol. 2022;919:174807. DOI
28. Belete TM. The current status of gene therapy for the treatment of cancer. Biol Targets Ther. 2021;2021:67-77. DOI PubMed PMC
29. Altanerova U, Jakubechova J, Benejova K, et al. Intracellular prodrug gene therapy for cancer mediated by tumor cell suicide gene
exosomes. Int J Cancer. 2021;148:128-39. DOI
30. Yanagisawa N, Satoh T, Tabata KI, et al. Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk +
ganciclovir gene therapy for prostate cancer. Asian J Urol. 2021;8:280-8. DOI PubMed PMC
31. Dhankhar R, Kawatra A, Mohanty A, Gulati P. Microbial enzymes used in prodrug activation for cancer therapy: insights and future
perspectives. Curr Protein Pept Sci. 2021;22:514-25. DOI PubMed
32. Mani R, Martin CG, Balu KE, et al. A novel protozoa parasite-derived protein adjuvant is effective in immunization with cancer cells
to activate the cancer-specific protective immunity and inhibit the cancer growth in a murine model of colorectal cancer. Cells.
2024;13:111. DOI PubMed PMC
33. Li J, Zeng H, Li L, Song M, Dong M. Biomembrane-wrapped gene delivery nanoparticles for cancer therapy. Front Bioeng
Biotechnol. 2023;11:1211753. DOI PubMed PMC
34. Wang I, Song L, Wang BY, Rezazadeh Kalebasty A, Uchio E, Zi X. Prostate cancer immunotherapy: a review of recent advancements
with novel treatment methods and efficacy. Am J Clin Exp Urol. 2022;10:210-33. PubMed PMC
35. Wang F, Li Z, Feng X, et al. Advances in PSMA-targeted therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:11-26.
DOI
36. Flugel CL, Majzner RG, Krenciute G, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat
Rev Clin Oncol. 2023;20:49-62. DOI PubMed PMC
37. Escudero-Lourdes C, Alvarado-Morales I, Tokar EJ. Stem cells as target for prostate cancer therapy: opportunities and challenges.
Stem Cell Rev Rep. 2022;18:2833-51. DOI PubMed PMC
38. Hafron JM, Wilfehrt HM, Ferro C, Harmon M, Flanders SC, McKay RR. Real-world effectiveness of sipuleucel-T on overall survival
in men with advanced prostate cancer treated with androgen receptor-targeting agents. Adv Ther. 2022;39:2515-32. DOI PubMed
PMC
39. Zanotta S, Galati D, De Filippi R, Pinto A. Enhancing dendritic cell cancer vaccination: the synergy of immune checkpoint inhibitors
in combined therapies. Int J Mol Sci. 2024;25:7509. DOI PubMed PMC
40. Perera Molligoda Arachchige AS. Human NK cells: from development to effector functions. Innate Immun. 2021;27:212-29. DOI
PubMed PMC
41. Gong Y, Klein Wolterink RGJ, Wang J, et al. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for
cancer therapy. J Hematol Oncol. 2021;14:73. DOI PubMed PMC
42. Bou-Dargham MJ, Sha L, Sang QA, Zhang J. Immune landscape of human prostate cancer: immune evasion mechanisms and
biomarkers for personalized immunotherapy. BMC Cancer. 2020;20:572. DOI PubMed PMC
43. Liu LL, Skribek M, Harmenberg U, Gerling M. Systemic inflammatory syndromes as life-threatening side effects of immune
checkpoint inhibitors: case report and systematic review of the literature. J Immunother Cancer. 2023;11:e005841. DOI PubMed
PMC
44. Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS. Targeting tumor suppressor p53 for cancer therapy: strategies,
challenges and opportunities. Curr Drug Targets. 2014;15:80-9. DOI PubMed
45. Han HA, Pang JKS, Soh BS. Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing. J Mol Med. 2020;98:615-32.
DOI PubMed PMC
46. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6:56. DOI
PubMed PMC